IndraLab

Statements

reach
"Flufenamic acid and mefenamic acid inhibit NLRP3 inflammasome activation through the suppression of chloride efflux."
29021150
reach
"Different NLRP3 inflammasome inhibitors, including sulforaphane, β-hydroxybutyrate, glyburide, flufenamic acid, mefenamic acid, parthenolide, BAY 11-7082, INF39, and MCC950 have been developed, but there is no evidence demonstrating that these compounds directly and specifically target NLRP3 itself (212)."
30619282
reach
"A few NLRP3 inflammasome inhibitors, including sulforaphane, isoliquiritigenin, beta-hydroxybutyrate (BHB), flufenamic acid, mefenamic acid, 3,4-methylenedioxy-beta-nitrostyrene (MNS), parthenolide, BAY 11-7082, INF39, and MCC950, have been developed, but there is no evidence showing that these compounds can specifically and directly inhibit NLRP3 itself."
29021150
reach
"In addition, flufenamic acid (FA), a member of non-steroidal anti-inflammatory drugs, was found to effectively inhibit activation of the microglial NLRP3 inflammasome by regulating Syk and AMPK."
35474599
reach
"Various Cl - channel inhibitors, including 4,4 '-diisothiocyano-2,2 ' stilbene-disulfonic acid (DIDS), 5-nitro-(3-phenylpropylamino) benzoic acid (NPPB), flufenamic acid, mefenamic acid, and indanyloxyacetic acid 94 (IAA94), block the NLRP3 inflammasome but can not block the NLRC4 or AIM2 inflammasomes."
33603747
reach
"XREF_BIBR Cl - channel blockers such as mefenamic acid, flufenamic acid, benzoic acid, etc, can inhibit the NLRP3 activation."
33814921